The CUT’HIVAC project is an innovative needle-free vaccination strategy across the skin to combat HIV and other infectious diseases.
Funded by the European Commission under the 7th Framework Programme, the collaboration spans 5 years and involves 13 partners across Europe, Africa, and South America.
The consortium combines expertise in HIV vaccine development, including DNA-GTU® and particle-based technologies, together with novel skin and mucosal routes of vaccine delivery, as well as pre-clinical, dermatological and clinical trials knowledge.
Financing entity: European Comission
Participant entities: Universite Pierre et Marie Curie, University of Regensburg, FIT Biotech Oy Ltd, CHARITE, St George’s University of London, MRC Medical Research Council, IMPACTA, Centre National de la Recherche Scientifique, INSERM, Instituto Nacional de Saúde, GENEART AG, NOVAMEN
Research Supervisor(s): Christian Brander